NL-OMON30949
Completed
Not Applicable
A double blind randomized study on the effectiveness of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in dark irided hypermetropic children - effectiveness of cycloplegics
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Eye strenght. Refraction
- Sponsor
- Medisch Centrum Haaglanden
- Enrollment
- 45
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy; not suffering from syndromes or diseases, 3 to 6 years (not attending group three of Dutch primary school system) old very dark irided hypermetropic children, possesing good accommodation, with no glasses prior or who did not wear their hypermetropic glasses since at least 4 weeks and able to fixate with each eye.
Exclusion Criteria
- •All children not possesing the inclusioncriteria (D4a)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
a double blind randomized study on the effectiveness of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in dark irided hypermetropic children - effectiveness of cycloplegicsrefraction of the eye/ refractive state of the eyeMedDRA version: 9.1Level: LLTClassification code 10038264Term: Refraction disorderEUCTR2007-003483-22-NLMedisch Centrum Haaglanden45
Active, not recruiting
Not Applicable
A double blind randomized study on the efficacy of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in children - Efficacy of cycloplegicsDepth of cycloplegiachanges of astigmatismrecuperation from cycloplegia and mydriasisMedDRA version: 12.1Level: LLTClassification code 10011719Term: CycloplegiaMedDRA version: 12.1Level: PTClassification code 10011719Term: CycloplegiaEUCTR2010-021410-34-NLMedical Centre Haaglanden423
Completed
Phase 3
A double blind randomized study on the efficacy of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in childreNL-OMON34025Medisch Centrum Haaglanden419
Active, not recruiting
Phase 1
Efficacy and Safety of REGN727 added-on to Rosuvastatin versus Ezetimibe added-on to Rosuvastatin versus Rosuvastatin dose increase in patients who are not controlled on RosuvastatiPatients with Non-familial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH) at high CV risk who are not adequately controlled with rosuvastatin (10mg or 20mg) with or without other lipid-modifying therapy (LMT) (excluding EZE)MedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2012-002333-11-ESRegeneron Pharmaceuticals, Inc.305
Active, not recruiting
Not Applicable
Efficacy and Safety of REGN727/SAR236553 added-on to Atorvastatin versus Ezetimibe added-on to Atorvastatin versus Atorvastatin dose increase versus switch to Rosuvastatin in patients who are not controlled on AtorvastatiEUCTR2012-002344-24-DERegeneron Pharmaceuticals, Inc.420